Clinical study on individualized medication of atorvastatin and rosuvastatin based on ABCB1(2677T＞G)gene polymorphism
Abstarct:Objective To study the effect of individualized medication advice based on ABCB1(2677T＞G)gene polymorphism on lipid-lowering efficacy.Methods A retrospective study was conducted.A total of 85 patients with hyperlipidemia hospitalized in the First Affiliated Hospital of Henan Polytechnic University from December 2020 to December 2022 were selected as subjects.All pa-tients were treated with atorvastatin or rosuvastatin for four weeks.The ABCB1(2677T＞G)gene polymorphism was detected by fluorescence in situ hybridization.patients were divided into advice-accepting group and advice-not-accepting group according to whether they accepted the individualized medication advice given based on ABCB1(2677T＞G)gene polymorphism.In the advice-accepting group,both TT and GT type patients took rosuvastatin,while GG type patients took atorvastatin.TT and GT type patients in the advice-not-accepting group all took atorvastatin,while GG type patients took rosuvastatin.Effect of individualized medication advice based on ABCB1(2677T＞G)gene polymorphism on lipid-lowering efficacy was studied,the change rate of blood lipid be-tween the two groups before and after treatment were compared.Results ABCB1(2677T＞G)gene frequency in 85 patients were GG(25 cases)29.41％,GT(33 cases)38.82％,TT(27 cases)31.77％,and the ABCB1(2677T＞G)genotype conformed to Hardy-Weinberg genetic balance.Before treatment,there was no significant difference in TC,HDL-C and LDL-C between the two groups.After treatment, there were significant differences in TC and LDL-C between the two groups (P ＜ 0.001), but there was no signifi-cant difference in HDL-C (P ＞ 0.05). It was found that the change rate of HDL-C in patients with ABCB1 2677TT genotype was sig-nificantly different (P ＜ 0.05). The change rates of TC, HDL-C and LDL-C in patients with ABCB1 2677GT genotype were signifi-cantly different (P ＜ 0.05, 0.01). The change rates of TC and LDL-C in patients with ABCB1 2677GG genotype were significantly different (P ＜ 0.05, 0.01). But the change rate of HDL-C was not significantly different (P ＞ 0.05). Conclusion Patients who accepted individualized medication advice based on ABCB1 (2677T ＞ G) gene polymorphism had significantly better effects in reducing TC and LDL-C levels than those who did not.
NETL
NSTL
万方数据
